ALZN – alzamend neuro, inc. (US:NASDAQ)
Stock Stats
News
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice [Yahoo! Finance]
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential [Yahoo! Finance]
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $50.00 to $35.00. They now have a "buy" rating on the stock.
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Form 8-K Alzamend Neuro, Inc. For: Oct 15
Form 424B5 Alzamend Neuro, Inc.
Form 8-K Alzamend Neuro, Inc. For: Oct 03
Form 10-Q Alzamend Neuro, Inc. For: Jul 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.